Products with Antioxidants bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5291 | Ziyuglycoside II |
| Ziyuglycoside II has a wide range of clinical applications including hemostasis, antibiosis, anti-inflammation and anti-oxidation. Ziyuglycoside II has inhibitory effect on the growth of MDA-MB-435 cells, it induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.Ziyuglycoside II methyl ester possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes. | |
| BCN5309 | Vestitol |
| Vestitol is a phytoalexin with insect feeding-deterrent activity, it has antioxidant, anti-inflammatory and antimicrobial activities, it can inhibit neutrophil migration at a dose of 10 mg/kg, and shows MICs ranging from 25-50 to 50-100 ug/mL and MBCs ranging from 25-50 to 50-100 ug/mL.Vestitol exerts a limited inhibitory effect on S. hermonthica germination, it can significantly inhibit seedling growth, it also contributes, at least in part, to the host's defence mechanism and acts as a chemical barrier against the intrusion of the parasite. | |
| BCN5310 | Ligustroside |
| 1. Ligustroside shows little antioxidant activity. 2. Ligustroside shows moderate antiviral activities against parainfluenza type 3 virus. 3. Ligustroside has anti-inflammatory properties, it shows a significant inhibition effect on prostaglandin E2 (PGE2)-release. | |
| BCN5318 | 3'-O-Methylorobol |
| 1. 3'-O-Methylorobol can increase osteoblast differentiation. 2. 3'-O-Methylorobol exerts potential analgesic properties. 3. 3'-O-Methylorobol exhibites moderate antioxidant activity in the 2,2-diphenyl-1-picrylhydrazyl free radical scavenging assay. | |
| BCN5319 | Jatrorrhizine |
| Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1. | |
